Juventas Cell Therapy Ltd.
Clinical trials sponsored by Juventas Cell Therapy Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- CAR-T therapy takes on tough blood disorder in early trial Results expected Sep 2026 (estimated)
- New cell injection aims to tame Hard-to-Treat autoimmune nerve disorders Results expected Dec 2026 (estimated)
- Experimental cell therapy targets Hard-to-Treat nerve diseases Results expected Jun 2027 (estimated)
-
Can engineered immune cells tame autoimmune anemia?
Cure Recruiting nowThis early-stage trial is testing an experimental treatment called HY001N, a type of CAR-T cell therapy, in adults with autoimmune hemolytic anemia (AIHA) who have not improved after three or more standard treatments. The goal is to see if the therapy is safe and tolerable, and w…
Phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
Experimental cell therapy targets Hard-to-Treat nerve diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called CNCT19 in 18 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The goal is to see if it is safe and can help control the disease by targeting certain immune cells. Partici…
Early phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC